PARP Inhibitors: Their Role in the Treatment of Ovarian Cancer
An educational community hospital series for community oncologists
The CME-accredited speaker series will interweave a didactic presentation with ARS for a unique interactive experience. Given the recent approval of several PARP inhibitors, as well as the associated volume of emerging data, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy, and prevent and manage adverse events (AEs). This program will help provide expert guidance to your institution regarding the use of existing PARP inhibitors and companion diagnostics safely and effectively, as well as to plan for optimal integration of new agents and indications into practice when they become available.
To request additional information or if you are interested in hosting one of these events at your community-based institution please click HERE to download and complete form. Please fax completed form to 1-800-210-8231 or email completed form to firstname.lastname@example.org.
Gynecologic oncologists, medical oncologists, and other allied healthcare providers caring for patients with ovarian cancer.
- Evaluate the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibitors
- Assess the role of PARP in DNA repair, as well as the rationale for targeting PARP in ovarian cancer patients with BRCA-mutated disease
- Appraise data of emerging PARP inhibitors undergoing clinical trial examination for proper use of current available PARP inhibitors
- Identify strategies to prevent and manage side effects of PARP inhibition to improve patient outcomes and adherence
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.